Literature DB >> 22406359

Role of cyclin D1 amplification and expression in vulvar carcinomas.

Matthias Choschzick1, Stephan Hess, Pierre Tennstedt, Frederik Holst, Hiltila Bohlken, Frederike Gieseking, Sven Mahner, Linn Woelber, Ronald Simon, Guido Sauter.   

Abstract

Cyclin D1 (CCND1) belongs to the family of D-type cyclins involved in cell cycle progression, transcriptional regulation, and cell migration. CCND1 was found to be amplified and overexpressed in a variety of cancers, including some vulvar carcinoma cell lines. To determine the relationship of CCND1 copy number changes and CCND1 protein expression with clinicopathologic features and prognosis, 183 vulvar carcinomas were analyzed on a tissue microarray. Amplification was observed in 32 (22.4%) vulvar cancer specimens and was statistically related to the presence of regional lymph node metastases (P < .001). Detectable CCND1 expression was found in 139 (83.2%) of vulvar carcinomas, and 76 (45.5%) exhibited a moderate or strong expression. Increased levels of CCND1 expression were significantly related to higher patient age (P = .013), positive pN category (P = .004), and negative human papillomavirus status (P < .001). Basaloid as well as verrucous, warty-type, and mixed vulvar carcinomas showed lower CCND1 expression levels than keratinizing or nonkeratinizing tumors (P < .001 and P = .032, respectively). Elevated CCND1 expression levels and amplification of the CCND1 gene were closely connected in the present analysis (P < .001). Patient prognosis was independent from CCND1 amplification status and expression level (P = .57 each). In conclusion, CCND1 is amplified and overexpressed in a substantial proportion of vulvar carcinomas and associated with the occurrence of locoregional lymph node metastases, especially in human papillomavirus-negative tumors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406359     DOI: 10.1016/j.humpath.2011.11.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma.

Authors:  Jeng-Wei Lu; Yueh-Min Lin; Jan-Gowth Chang; Kun-Tu Yeh; Rong-Ming Chen; Jeffrey J P Tsai; Wei-Wen Su; Rouh-Mei Hu
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

Review 2.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553

Review 3.  An update: emerging drugs to treat squamous cell carcinomas of the head and neck.

Authors:  Yoon Se Lee; Daniel E Johnson; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2018-11-16       Impact factor: 4.191

Review 4.  Molecular events in the pathogenesis of vulvar squamous cell carcinoma.

Authors:  Deyin Xing; Oluwole Fadare
Journal:  Semin Diagn Pathol       Date:  2020-09-25       Impact factor: 3.464

5.  Genome-Wide Association Study Identified a Quantitative Trait Locus and Two Candidate Genes on Sus scrofa Chromosome 2 Affecting Vulvar Traits of Suhuai Pigs.

Authors:  Yanzhen Yin; Liming Hou; Chenxi Liu; Kaijun Li; Hao Guo; Peipei Niu; Qiang Li; Ruihua Huang; Pinghua Li
Journal:  Genes (Basel)       Date:  2022-07-22       Impact factor: 4.141

6.  Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells.

Authors:  Kalliopi I Pappa; Alexander Polyzos; Jasmine Jacob-Hirsch; Ninette Amariglio; George D Vlachos; Dimitrios Loutradis; Nicholas P Anagnou
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

7.  Molecular heterogeneity in human papillomavirus-dependent and -independent vulvar carcinogenesis.

Authors:  Dorian R A Swarts; Quirinus J M Voorham; Annina P van Splunter; Saskia M Wilting; Daoud Sie; Divera Pronk; Marc van Beurden; Daniëlle A M Heideman; Peter J F Snijders; Chris J L M Meijer; Renske D M Steenbergen; Maaike C G Bleeker
Journal:  Cancer Med       Date:  2018-07-20       Impact factor: 4.452

8.  Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets.

Authors:  Erik A Williams; Adrienne J Werth; Radwa Sharaf; Meagan Montesion; Ethan S Sokol; Dean C Pavlick; Molly McLaughlin-Drubin; Rachel Erlich; Helen Toma; Kevin Jon Williams; Jeff M Venstrom; Brian M Alexander; Nikunj Shah; Natalie Danziger; Amanda C Hemmerich; Eric A Severson; Jonathan Keith Killian; Douglas I Lin; Jeffrey S Ross; Julie Y Tse; Shakti H Ramkissoon; Mark C Mochel; Julia A Elvin
Journal:  JCO Precis Oncol       Date:  2020-06-16

9.  Transcriptome Analysis in Vulvar Squamous Cell Cancer.

Authors:  Katharina Prieske; Malik Alawi; Anna Jaeger; Maximilian Christian Wankner; Kathrin Eylmann; Susanne Reuter; Patrick Lebok; Eike Burandt; Niclas C Blessin; Barbara Schmalfeldt; Leticia Oliveira-Ferrer; Simon A Joosse; Linn Woelber
Journal:  Cancers (Basel)       Date:  2021-12-19       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.